New Phase 3 Data Reinforces Safety, Efficacy of Linaclotide

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Related Keywords

Rome , Lazio , Italy , Georgee Batchelor , Michael Shetzline , Drug Administration , University Of Miami , Ironwood Pharmaceuticals Announces , Ironwood Pharmaceuticals , University Of Miami Health System Miguel Saps , Miami Health System , Miguel Saps , Lancet Gastroenterology , Endowed Chair , Bristol Stool Form Scale , Ironwood Announces Publication , New Linaclotide Phase , Adolescents Aged , New Indication , Functional Constipation , Pediatric Patients Ages , Linaclotide , Linzess , Chronic Idiopathic Constipation , Irritable Bowel Syndrome , Ribs , Constipation , Stool , Bowel Movement ,